Abstract:Background: Acute myeloid leukemia (AML) is a highly aggressive and pathogenic hematologic malignancy with consistently high mortality. Lysosomes are organelles involved in cell growth and metabolism that fuse to form specialized Auer rods in AML, and their role in AML has not been elucidated. This study aimed to identify AML subtypes centered on lysosome-related genes and to construct a prognostic model to guide individualized treatment of AML. Methods: Gene expression data and clinical data from AML patients were downloaded from two high-throughput sequencing platforms. The 191 lysosomal signature genes were obtained from the database MsigDB. Lysosomal clusters were identified by unsupervised consensus clustering. The differences in molecular expression, biological processes, and the immune microenvironment among lysosomal clusters were subsequently analyzed. Based on the molecular expression differences between lysosomal clusters, lysosomal-related genes affecting AML prognosis were screened by univariate cox regression and multivariate cox regression analyses. Algorithms for LASSO regression analyses were employed to construct prognostic models. The risk factor distribution, KM survival curve, was applied to evaluate the survival distribution of the model. Time-dependent ROC curves, nomograms and calibration curves were used to evaluate the predictive performance of the prognostic models. TIDE scores and drug sensitivity analyses were used to explore the implication of the model for AML treatment. Results: Our study identified two lysosomal clusters, cluster1 has longer survival time and stronger immune infiltration compared to cluster2. The differences in biological processes between the two lysosomal clusters are mainly manifested in the lysosomes, vesicles, immune cell function, and apoptosis. The prognostic model consisting of six prognosis-related genes was constructed. The prognostic model showed good predictive performance in all three data sets. Patients in the low-risk group survived significantly longer than those in the high-risk group and had higher immune infiltration and stronger response to immunotherapy. Patients in the high-risk group showed greater sensitivity to cytarabine, imatinib, and bortezomib, but lower sensitivity to ATRA compared to low -risk patients. Conclusion: Our prognostic model based on lysosome-related genes can effectively predict the prognosis of AML patients and provide reference evidence for individualized immunotherapy and pharmacological chemotherapy for AML.

Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients

Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapy

Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia

A Distinct Glucose Metabolism Signature of Acute Myeloid Leukemia with Prognostic Value.

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Comprehensive Analysis of Prognostic Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes

Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy

NDRG2 and TLR7 As Novel DNA Methylation Prognostic Signatures for Acute Myelocytic Leukemia.

Identifying a prognostic model and screening of potential natural compounds for acute myeloid leukemia

Rapid Diagnosis and Prognosis of De Novo Acute Myeloid Leukemia by Serum Metabonomic Analysis.

Prognostic implications of metabolism-related genes in acute myeloid leukemia

A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia

Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia

[Preliminarily Screening of Serum Characteristic Markers in Acute Myeloid Leukemia and Clinical Significance].

Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia

A Metabolome and Microbiome Analysis of Acute Myeloid Leukemia: Insights into the Carnosine–Histidine Metabolic Pathway

Research progress on molecular biomarkers of acute myeloid leukemia

Glutamine metabolism-related genes predict the prognostic risk of acute myeloid leukemia and stratify patients by subtype analysis

Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML

Metabolomics analysis of salvage chemotherapy on refractory acute myeloid leukemia patients.

Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling